NNDM Stock Jumps 6%: Nano Dimension’s Cash-Rich Reset Faces Its Next Test

May 22, 2026
NNDM Stock Jumps 6%: Nano Dimension’s Cash-Rich Reset Faces Its Next Test

New York, May 21, 2026, 19:03 EDT

  • Nano Dimension’s U.S.-listed ADSs rose 5.9% to $1.61, with volume near 1.65 million shares.
  • The gain outpaced the Nasdaq’s 0.1% rise and came as investors kept focus on the company’s strategic review.
  • The next test is whether asset sales and deal options can cut losses without eroding the balance sheet.

Nano Dimension Ltd.’s Nasdaq-listed American Depositary Shares rose 5.9% to $1.61 on Thursday, lifting the Israeli digital manufacturing company’s market value to about $334 million after a stronger day for smaller technology and industrial names. ADSs are U.S.-traded certificates that represent shares in a foreign company.

Why now: the stock is trading less on fresh operating news than on the company’s ongoing reset. Nano Dimension has told investors it is cutting cash burn, the rate at which it spends money, selling product lines and reviewing strategic alternatives, including potential transactions.

That matters because the market value still sits below the $441.6 million in cash, deposits, restricted deposits and marketable equity securities the company reported at March 31. Chief Executive David Stehlin said this month the company had narrowed its review to a “short list” of strategic alternatives, while full-year 2026 guidance was suspended because the business could still change materially. GlobeNewswire

Nano’s shares also moved with the additive-manufacturing group. 3D Systems rose about 8.1%, while Stratasys gained about 2.2%; Google Finance showed Nano at $1.62 in after-hours trading, up another 0.6%.

The broader market helped. The Nasdaq Composite edged up 0.1% to 26,293.10 and the Russell 2000, a small-cap index, gained 0.9%, according to AP market data. U.S. equity markets traded a normal session Thursday, with Nasdaq listing Memorial Day, Monday, May 25, as the next full market closure.

Nano Dimension reported first-quarter revenue of $29.7 million, up 106% from a year earlier, helped by the inclusion of Markforged. But the company’s net loss widened to $69.7 million, including a $40.4 million impairment, an accounting write-down that does not use cash but signals reduced asset value.

Management has moved to shrink the portfolio. In April, Nano agreed to sell its additively manufactured electronics and Fabrica product lines to Inspira Technologies for up to $12.5 million, including $2 million upfront and up to $10.5 million tied to future performance. Stehlin said that sale would lower operating costs and cash burn while preserving possible upside.

On the earnings call, Chief Financial Officer John Brenton said Nano’s financial position remained “exceptionally strong,” though he also said standalone revenue fell about 12%, excluding Markforged, due to tariffs and divestments. Stehlin pushed back on a shareholder comparison to a blank-check company, saying Nano was “absolutely not a SPAC.” Investing

But the risk is plain. A higher share price could fade if the strategic review produces another complex deal, if asset sales fetch less than hoped, or if losses keep draining cash faster than management’s cuts can offset. The company’s adjusted EBITDA loss — earnings before interest, taxes, depreciation and amortization, excluding certain items — widened to $12.5 million in the quarter from $10.1 million a year earlier.

For now, investors are paying for optionality: cash, a Nasdaq listing, assets that can be sold, and a board looking for a larger move. The next few weeks may show whether that optionality is worth more than the balance sheet, or whether the stock’s bounce was just another short burst in a still-unfinished turnaround.

Stock Market Today

  • Bell Potter Upgrades Doctor Care Anywhere with 75% Upside on MedicSpot Acquisition
    May 21, 2026, 7:44 PM EDT. Bell Potter has upgraded UK-based telehealth firm Doctor Care Anywhere Group PLC (ASX: DOC) to Buy from Hold, citing a pivotal acquisition of MedicSpot. The deal expands DOC's service from a single client to a more diversified corporate healthcare platform, combining GP, musculoskeletal, mental health, and weight management services. Bell Potter values MedicSpot at £850,000, noting near breakeven EBITDA and entry into the direct-to-consumer (D2C) wellness market. The broker raised the 12-month price target to 24 cents from 20 cents, signaling a 75% potential upside from the current 13.7 cents. The acquisition addresses DOC's prior gap in weight management programs, enhancing competitiveness in UK healthcare tenders, according to Bell Potter.